<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250782</url>
  </required_header>
  <id_info>
    <org_study_id>GlnHSD-001-09</org_study_id>
    <nct_id>NCT01250782</nct_id>
  </id_info>
  <brief_title>Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.</brief_title>
  <acronym>GluTrac</acronym>
  <official_title>Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Son Dureta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Son Dureta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent reports suggest that most beneficial results of glutamine have been obtained with the
      parenteral administration of high doses of glutamine (0.35 g/Kg/d) and in some special group
      of patients, such as traumatic patients. Nevertheless total parenteral nutrition is not often
      used in critically ill patients.

      The endovenous administration of the the dipeptide N(2)-L-alanyl-L-glutamine in trauma ICU
      patients can reduce the number of infections, ICU length of stay and mortality.

      This benefit can be achieved independently the type of nutrition (enteral or parenteral
      nutrition), being a pharmaconutrient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To evaluate the efficacy of the endovenous administration endovenous glutamine to
      reduce the number of infectious complications, mortality and ICU length of stay in trauma ICU
      patients. To achieve this objective we have designed this pilot study to obtain the necessary
      data to design a bigger trial in the future.

      Other objectives include:

        -  To evaluate the efficacy of glutamine in different patients regarding their severity:
           patients with an Injury Severity Score&gt; 25 and patients with lower plasma levels of
           glutamine.

        -  To registry the possible adverse events of the endovenous administration of glutamine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of infections</measure>
    <time_frame>ICU discharge (median ten days)</time_frame>
    <description>Based on the results of the ENVIN trial, the median ICU length of stay of trauma patients admitted to the ICU in Spain, is 10 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>ICU mortality measured at 1 month after hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAfety of endovenous administration</measure>
    <time_frame>5 days from the beginning of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Trauma ICU Patients</condition>
  <arm_group>
    <arm_group_label>Physiological Serum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine</description>
    <arm_group_label>Glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological serum</intervention_name>
    <description>100 mL of physiological serum indistinguishable from active comparator</description>
    <arm_group_label>Physiological Serum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe trauma, as defined by an Injury Severity Score (ISS) &gt; 10 points
             were included in the study.

          -  Traumatic patients who required enteral or parenteral nutrition during the first 48
             hours after hospital admission

          -  Written informed consent

        Exclusion Criteria:

          -  patients whose life expectancy was less than 5 days,

          -  who were allergic to glutamine,

          -  Patients included in any other trial

          -  Cirrhotic patients (Child C)

          -  Chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Son Dureta</name>
      <address>
        <city>Palma</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Pérez-Barcena, MD</last_name>
      <phone>34 971 17 51 52</phone>
      <email>juan.perez@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Pedro Marsé-Milla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pedro Marsé-Milla</name_title>
    <organization>Hospital Universitari Son Dureta</organization>
  </responsible_party>
  <keyword>Glutamine, trauma patients, infections, mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

